- Home
- ISPR vs IKT Comparison
ISPR vs IKT Comparison
Compare ISPR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- IKT
- Stock Information
- Founded
- ISPR 2019
- IKT 2008
- Country
- ISPR United States
- IKT United States
- Employees
- ISPR N/A
- IKT N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- IKT Health Care
- Exchange
- ISPR Nasdaq
- IKT Nasdaq
- Market Cap
- ISPR 152.0M
- IKT 140.5M
- IPO Year
- ISPR 2023
- IKT 2020
- Fundamental
- Price
- ISPR $3.06
- IKT $1.80
- Analyst Decision
- ISPR Strong Buy
- IKT Buy
- Analyst Count
- ISPR 2
- IKT 2
- Target Price
- ISPR $10.00
- IKT $8.00
- AVG Volume (30 Days)
- ISPR 47.6K
- IKT 98.2K
- Earning Date
- ISPR 09-19-2025
- IKT 08-14-2025
- Dividend Yield
- ISPR N/A
- IKT N/A
- EPS Growth
- ISPR N/A
- IKT N/A
- EPS
- ISPR N/A
- IKT N/A
- Revenue
- ISPR $144,700,345.00
- IKT N/A
- Revenue This Year
- ISPR N/A
- IKT N/A
- Revenue Next Year
- ISPR $35.39
- IKT N/A
- P/E Ratio
- ISPR N/A
- IKT N/A
- Revenue Growth
- ISPR N/A
- IKT N/A
- 52 Week Low
- ISPR $2.09
- IKT $1.12
- 52 Week High
- ISPR $7.79
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ISPR 66.49
- IKT 52.36
- Support Level
- ISPR $2.74
- IKT $1.77
- Resistance Level
- ISPR $3.43
- IKT $1.87
- Average True Range (ATR)
- ISPR 0.19
- IKT 0.15
- MACD
- ISPR 0.05
- IKT 0.02
- Stochastic Oscillator
- ISPR 82.67
- IKT 72.97
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.